Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT

Masayuki Sasaki, Yasuo Kuwabara, Yuichi Ichiya, Tsuyoshi Yoshida, Makoto Nakagawa, Hiroyasu Soeda, Kenji Sugio, Yoshihiko Maehara, Kouji Masuda

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) has been reported to accumulate in various tumors and to be a transport substrate for P- glycoprotein (Pgp). The aim of this study was to evaluate the usefulness of 99mTc-MIBI SPECT for in vivo assessment of lung cancer chemosensitivity. Also examined was the relationship between 99mTc-MIBI uptake and Pgp expression. Methods: Ten lung cancer patients who had undergone surgery were examined. Before surgery, 99mTc-MIBI SPECT was performed 15 and 120 min after injection, and the early uptake (L/Ne), delayed uptake (L/Nd) and washout rate (L/Nwr) of 99mTc-MIBI were calculated by the count ratio of lesion to contralateral normal lung tissue. The results were then compared with chemosensitivity determined by the succinate dehydrogenase inhibition test using six antitumor drugs (doxorubicin, mitomycin C [MMC], vindesine, etoposide [VP-16], cyclophosphamide and cisplatin). Pgp expression was determined by immunohistochemical staining. Results: Sensitivity to MMC correlated significantly with L/Ne (P < 0.01) and L/Nwr (P < 0.05). Sensitivity to VP-16 correlated weakly and insignificantly with L/Nwr. L/Nd showed no correlation with sensitivity to any drug. Neither L/Ne, L/Nd nor L/Nwr was significantly different between the Pgp-positive group (n = 2) and the Pgp-negative group (n = 8). Conclusion: The results suggest that 99mTc-MIBI SPECT, a noninvasive in vivo examination, can predict the chemosensitivity of lung cancer to MMC and VP-16 independently of Pgp expression.

Original languageEnglish
Pages (from-to)1778-1783
Number of pages6
JournalJournal of Nuclear Medicine
Volume40
Issue number11
Publication statusPublished - Nov 1999

Fingerprint

P-Glycoprotein
Single-Photon Emission-Computed Tomography
Etoposide
Lung Neoplasms
Mitomycin
Vindesine
Succinate Dehydrogenase
Antineoplastic Agents
Doxorubicin
Cyclophosphamide
Cisplatin
Staining and Labeling
Lung
Injections
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Sasaki, M., Kuwabara, Y., Ichiya, Y., Yoshida, T., Nakagawa, M., Soeda, H., ... Masuda, K. (1999). Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT. Journal of Nuclear Medicine, 40(11), 1778-1783.

Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT. / Sasaki, Masayuki; Kuwabara, Yasuo; Ichiya, Yuichi; Yoshida, Tsuyoshi; Nakagawa, Makoto; Soeda, Hiroyasu; Sugio, Kenji; Maehara, Yoshihiko; Masuda, Kouji.

In: Journal of Nuclear Medicine, Vol. 40, No. 11, 11.1999, p. 1778-1783.

Research output: Contribution to journalArticle

Sasaki, M, Kuwabara, Y, Ichiya, Y, Yoshida, T, Nakagawa, M, Soeda, H, Sugio, K, Maehara, Y & Masuda, K 1999, 'Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT', Journal of Nuclear Medicine, vol. 40, no. 11, pp. 1778-1783.
Sasaki M, Kuwabara Y, Ichiya Y, Yoshida T, Nakagawa M, Soeda H et al. Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT. Journal of Nuclear Medicine. 1999 Nov;40(11):1778-1783.
Sasaki, Masayuki ; Kuwabara, Yasuo ; Ichiya, Yuichi ; Yoshida, Tsuyoshi ; Nakagawa, Makoto ; Soeda, Hiroyasu ; Sugio, Kenji ; Maehara, Yoshihiko ; Masuda, Kouji. / Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT. In: Journal of Nuclear Medicine. 1999 ; Vol. 40, No. 11. pp. 1778-1783.
@article{73ad6dd24ec046f280e987fc78f6013d,
title = "Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT",
abstract = "99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) has been reported to accumulate in various tumors and to be a transport substrate for P- glycoprotein (Pgp). The aim of this study was to evaluate the usefulness of 99mTc-MIBI SPECT for in vivo assessment of lung cancer chemosensitivity. Also examined was the relationship between 99mTc-MIBI uptake and Pgp expression. Methods: Ten lung cancer patients who had undergone surgery were examined. Before surgery, 99mTc-MIBI SPECT was performed 15 and 120 min after injection, and the early uptake (L/Ne), delayed uptake (L/Nd) and washout rate (L/Nwr) of 99mTc-MIBI were calculated by the count ratio of lesion to contralateral normal lung tissue. The results were then compared with chemosensitivity determined by the succinate dehydrogenase inhibition test using six antitumor drugs (doxorubicin, mitomycin C [MMC], vindesine, etoposide [VP-16], cyclophosphamide and cisplatin). Pgp expression was determined by immunohistochemical staining. Results: Sensitivity to MMC correlated significantly with L/Ne (P < 0.01) and L/Nwr (P < 0.05). Sensitivity to VP-16 correlated weakly and insignificantly with L/Nwr. L/Nd showed no correlation with sensitivity to any drug. Neither L/Ne, L/Nd nor L/Nwr was significantly different between the Pgp-positive group (n = 2) and the Pgp-negative group (n = 8). Conclusion: The results suggest that 99mTc-MIBI SPECT, a noninvasive in vivo examination, can predict the chemosensitivity of lung cancer to MMC and VP-16 independently of Pgp expression.",
author = "Masayuki Sasaki and Yasuo Kuwabara and Yuichi Ichiya and Tsuyoshi Yoshida and Makoto Nakagawa and Hiroyasu Soeda and Kenji Sugio and Yoshihiko Maehara and Kouji Masuda",
year = "1999",
month = "11",
language = "English",
volume = "40",
pages = "1778--1783",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2- methoxyisobutyl isonitrile SPECT

AU - Sasaki, Masayuki

AU - Kuwabara, Yasuo

AU - Ichiya, Yuichi

AU - Yoshida, Tsuyoshi

AU - Nakagawa, Makoto

AU - Soeda, Hiroyasu

AU - Sugio, Kenji

AU - Maehara, Yoshihiko

AU - Masuda, Kouji

PY - 1999/11

Y1 - 1999/11

N2 - 99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) has been reported to accumulate in various tumors and to be a transport substrate for P- glycoprotein (Pgp). The aim of this study was to evaluate the usefulness of 99mTc-MIBI SPECT for in vivo assessment of lung cancer chemosensitivity. Also examined was the relationship between 99mTc-MIBI uptake and Pgp expression. Methods: Ten lung cancer patients who had undergone surgery were examined. Before surgery, 99mTc-MIBI SPECT was performed 15 and 120 min after injection, and the early uptake (L/Ne), delayed uptake (L/Nd) and washout rate (L/Nwr) of 99mTc-MIBI were calculated by the count ratio of lesion to contralateral normal lung tissue. The results were then compared with chemosensitivity determined by the succinate dehydrogenase inhibition test using six antitumor drugs (doxorubicin, mitomycin C [MMC], vindesine, etoposide [VP-16], cyclophosphamide and cisplatin). Pgp expression was determined by immunohistochemical staining. Results: Sensitivity to MMC correlated significantly with L/Ne (P < 0.01) and L/Nwr (P < 0.05). Sensitivity to VP-16 correlated weakly and insignificantly with L/Nwr. L/Nd showed no correlation with sensitivity to any drug. Neither L/Ne, L/Nd nor L/Nwr was significantly different between the Pgp-positive group (n = 2) and the Pgp-negative group (n = 8). Conclusion: The results suggest that 99mTc-MIBI SPECT, a noninvasive in vivo examination, can predict the chemosensitivity of lung cancer to MMC and VP-16 independently of Pgp expression.

AB - 99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) has been reported to accumulate in various tumors and to be a transport substrate for P- glycoprotein (Pgp). The aim of this study was to evaluate the usefulness of 99mTc-MIBI SPECT for in vivo assessment of lung cancer chemosensitivity. Also examined was the relationship between 99mTc-MIBI uptake and Pgp expression. Methods: Ten lung cancer patients who had undergone surgery were examined. Before surgery, 99mTc-MIBI SPECT was performed 15 and 120 min after injection, and the early uptake (L/Ne), delayed uptake (L/Nd) and washout rate (L/Nwr) of 99mTc-MIBI were calculated by the count ratio of lesion to contralateral normal lung tissue. The results were then compared with chemosensitivity determined by the succinate dehydrogenase inhibition test using six antitumor drugs (doxorubicin, mitomycin C [MMC], vindesine, etoposide [VP-16], cyclophosphamide and cisplatin). Pgp expression was determined by immunohistochemical staining. Results: Sensitivity to MMC correlated significantly with L/Ne (P < 0.01) and L/Nwr (P < 0.05). Sensitivity to VP-16 correlated weakly and insignificantly with L/Nwr. L/Nd showed no correlation with sensitivity to any drug. Neither L/Ne, L/Nd nor L/Nwr was significantly different between the Pgp-positive group (n = 2) and the Pgp-negative group (n = 8). Conclusion: The results suggest that 99mTc-MIBI SPECT, a noninvasive in vivo examination, can predict the chemosensitivity of lung cancer to MMC and VP-16 independently of Pgp expression.

UR - http://www.scopus.com/inward/record.url?scp=0032744476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032744476&partnerID=8YFLogxK

M3 - Article

C2 - 10565770

AN - SCOPUS:0032744476

VL - 40

SP - 1778

EP - 1783

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -